Breast cancer drug tested on bladder
Published: Feb. 27, 2008 at 7:33 PM
NEW YORK, Feb. 27 (UPI) -- U.S. researchers will test Abraxane -- a drug used to treat metastatic breast cancer -- as an alternative to bladder-removal-surgery for cancer patients.
Researchers at the NewYork-Presbyterian Hospital and Columbia University Medical Center in New York will be using Abraxane, a drug approved by the U.S. Food and Drug Administration for breast cancer, after a successful phase l trial involving bladder cancer patients of a similar breast cancer drug --Taxotere.
"Abraxane has an analogous structure to Taxotere, but has the advantage of being more soluble due to its solvent-free formulation allowing for administration at higher concentrations," study leader Dr. James McKiernanm, who was also involved in the Taxotere trial, said in a statement. "In one study of Abraxane for metastatic breast cancer, the drug successfully shrank tumors and had few side effects."
The phase l/ll study of Abraxane -- open to patients with recurrent bladder cancer that has not responded to standard treatment and left with surgical removal of the bladder as the only option -- will follow 18 patients for six weeks to assess dosage safety. A second group of l9 patients will then be followed for six weeks to measure the effectiveness of therapy.
Abraxane combines the chemotherapy drug paclitaxel, with albumin, a very small protein.
Researchers at the NewYork-Presbyterian Hospital and Columbia University Medical Center in New York will be using Abraxane, a drug approved by the U.S. Food and Drug Administration for breast cancer, after a successful phase l trial involving bladder cancer patients of a similar breast cancer drug --Taxotere.
"Abraxane has an analogous structure to Taxotere, but has the advantage of being more soluble due to its solvent-free formulation allowing for administration at higher concentrations," study leader Dr. James McKiernanm, who was also involved in the Taxotere trial, said in a statement. "In one study of Abraxane for metastatic breast cancer, the drug successfully shrank tumors and had few side effects."
The phase l/ll study of Abraxane -- open to patients with recurrent bladder cancer that has not responded to standard treatment and left with surgical removal of the bladder as the only option -- will follow 18 patients for six weeks to assess dosage safety. A second group of l9 patients will then be followed for six weeks to measure the effectiveness of therapy.
Abraxane combines the chemotherapy drug paclitaxel, with albumin, a very small protein.
© 2008 United Press International. All Rights Reserved.
This material may not be reproduced, redistributed, or manipulated in any form.
This material may not be reproduced, redistributed, or manipulated in any form.
» Next in Health:
Anti-HIV gel well tolerated by women
Latest Headlines
Most Popular
- Cows stampede on California highway
- Parakeet eggs lure man into live wire
- New York teachers learn cell phone lessons
- Florida deputy bitten by gator
- Arrest in 1991 'Point Break' robbery
- Thong helps Giambi out of slumps
- Woman with large cyst told to lose weight
- Bus group wants 'gentler' female drivers